Micrus Endovascular — Merger or Acquisition (July 2010)
16 slides from Micrus Endovascular's merger presentation, Jul 12, 2010
Slide 1: Introduction to Codman: A Global Medical Device Company
INTRODUCTION TO CODMAN: A Global Medical Device Company Leading the Evolution in Neuroscience July, 2010
Slide 2: Our Mission
Our Mission: To Improve the quality of life in many more patients worldwide by developing innovative solutions across a broad spectrum of neurological conditions
Slide 3: J&J's Global Presence
$23.6B $15.8B $22.5B J&J’s Global Presence • One of the World’s Largest Health Care Companies • 115,000 Employees • 250 Operating Companies In 57 Countries • Selling Products in Over 175 Countries Diversified Business Medical Devices & Diagnostics 38% Consumer 26% Pharmaceutical 36%
Slide 4: Our Credo responsibilities
“We believe our first responsibility is to doctors, nurses and patients…” “We are also responsible to the communities we serve…” “Our final responsibility is to our stockholders…” “We are also responsible to our employees…”
Slide 5: The DePuy Companies of Johnson & Johnson
Sports Medicine and Minimally Invasive Joint Therapies Joint Reconstruction and Trauma Neurological and Neurovascular Treatment The DePuy Companies of Johnson & Johnson
Slide 6: Add Images of R&D, product, physician
6 Add Images of R&D, product, physician with company, physician with patient
Slide 7: Codman global footprint and facilities
7 • Products sold in over 50 countries • Global workforce of over 500 people • Worldwide headquarters: • Raynham, MA • Manufacturing locations: • Massachusetts • Germany • Switzerland • Mexico
Slide 8: Codman & Shurtleff is Creating a Global Presence in Neuroscience
Codman & Shurtleff, Inc. is Creating a Global Presence in Neuroscience • A Total Neuroscience Company with a broad product line • From a Foundation with Neurosurgeons worldwide • Integrated Cordis neurovascular (CNV) business into Codman in 2009 • Launched MEDSTREAM neuromodulation drug pump in 2009
Slide 9: Vast Unmet Need Remains in Treating Neurological Disorders
Each year, there are over 30 million newly diagnosed patients worldwide with neurological disease Vast Unmet Need Remains in Treating Neurological Disorders Ø Worldwide, 1-in-5, or 1.7billion people, suffer from neurological diseases, yet less than 1-in-5 of these people are treated § In the US, Str
Slide 10: We Offer an Industry-leading Product Portfolio
We Offer an Industry-leading Product Portfolio Major Conditions / Diseases Products • Acquired hydrocephalus (via. tumor, surgery, absorption) • Normal Pressure Hydro (NPH) Hydrocephalus Treat Valves: Fixed and CHPV® BACTISEAL® Catheter • Post-craniotomy care • Traumatic Brain Injury (TBI) • (post)
Slide 11: We are investing in Transformational Technologies
We are investing in Transformational Technologies* Neuromodulation Stroke Therapeutics & Diagnostics Neurosurgery & NeuroCritical Care Neurostimulators SNS Selective nerve stimulation for under-treated diseases, including epilepsy, depression, stroke Drug Delivery Build on MEDSTREAM pump with new co
Slide 12: Competitive Advantages
Competitive Advantages ENTERPRISE Stent Platform Global Footprint & Alignment World-class Prof Ed Capabilities Codman: Total Neurosciences Approach
Slide 13: DePuy Institute, LLC
DePuy Institute, LLC State-of-the-art 70,000 sq ft facility • Hydrocephalus • Neurovascular • Neuro Critical Care • Raising Awareness • NPH Patient Campaign • NPH Referral Development • Professional Education • Hydro Symposia • Embolic Training Courses • New DePuy Institute Addressing the unmet educ
Slide 14: Our Commitment
Our Commitment Strengthen Global Presence in Neuroscience Offer an Industry-leading Product Portfolio Advance Breakthrough Future Therapies
Slide 15: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties mat
Slide 16: Additional information about the proposed transaction
In connection with the proposed transaction, Micrus Endovascular Corporation intends to file a definitive proxy statement and other relevant materials with the Securities and Exchange Commission (the “SEC”). Before making any voting decision with respect to the proposed transaction, stockholders of
Micrus Endovascular — Merger or Acquisition (July 2010) on 6ix